CAR-T Therapies: Failure To Meet Release Specifications May Not Bar Patient Use
Executive Summary
Some patients in Novartis' pediatric leukemia pivotal trial for tisagenlecleucel (CTL019) received out-of-spec product following the sponsor's consultation with US FDA, and the same thing might occur in the commercial setting.